First, last, corresponding authors

This is a list of 2025 publications with cancer center members as either first, last, or corresponding author arranged by highest impact factor.

Chen, X, Shen, Y, Choi, S, Abdel-Hafiz HA, Basu M, Hoelzen L, & Theodorescu, D. Concurrent loss of the Y chromosome in cancer and T cells impacts outcome. Nature.  2025, June 4. Impact factor: 69.5

Scott AJ, Kennedy EB, Gholami S. Reply to: Should Total Neoadjuvant Therapy Be the First-Line Treatment for Patients With Locally Advanced Rectal Cancer? J Clin Oncol. 2025,  March 10;:JCO2402435. Impact factor: 44.5

Yang J, Lim JT, Santiago Raj PV, Corona MG, Chen C, Khawaja H, Pan Q, Paine-Murrieta GD, Schnellmann RG, Roe DJ, Gokhale PC, DeCaprio JA, Padi M. Integrative analysis reveals therapeutic potential of pyrvinium pamoate in Merkel cell carcinoma. J Clin Invest. 2025, Feb. 11. Impact factor: 14.8

Coronado G, Rutter C. Response to McElroy and Everett. J Natl Cancer Inst. 2025, June 1. PMCID: PMC12145911. Impact factor: 13.5

Mesgarzadeh S, Myrdal CN, Gong AH, Stratton DB, Kelly BG, Curiel-Lewandrowski C. Heterogeneity among melanoma databases and challenges in sustainability: A survey of the Melanoma Prevention Working Group. JAAD Int. 2025, Feb. 1;18:137-139. PMCID: PMC11697841. Impact factor: 12.8

Clements AN, Casillas AL, Flores CE, Liou H, Toth RK, Chauhan SS, Sutterby K, Deshmukh SK, Wu S, Xiu J, Farrell A, Radovich M, Nabhan C, Heath EI, McKay RR, Subah N, Centuori S,  Wheeler TJ, Cress AE, Rogers GC, Wilson JE, Recio-Boiles A, Warfel NA. Inhibition of PIM kinase in tumor-associated macrophages suppresses inflammasome activation and sensitizes prostate cancer to immunotherapy. Cancer Immunol Res. 2025, May 2;13(5):633-645. Impact factor: 12

Chee D,  Ong CEY,  Tan DJ,  Schattenberg JM,  Ioannou GN,  Huang DQ,  Wijarnpreecha, K.  HCC Policy Study Group. Global health policies for hepatocellular carcinoma: a cross-sectional study. Clin Gastroenterol Hepatol. 2025, May 12: S1542-3565(25)00364-7. Impact factor: 11.3

Jiang Y, Wang Z, Li W, Ma T, Li M,  Wu S, Lin E, Flader KE, Ma M, Chang M, Li H, Wang W, Lu J. Enhanced Delivery of Camptothecin to Colorectal Carcinoma Using a Tumor-Penetrating Peptide Targeting p32. Acta Biomater. 2025 Jun 15;200:629-640. Impact factor: 10.6

Carew JS, Espitia CM, Sureshkumar S, Carrera Espinoza MJ, Gamble ME, Wang W, Lee BR, Nawrocki ST. REDD1 is a determinant of the sensitivity of renal cell carcinoma cells to autophagy inhibition that can be therapeutically exploited by targeting PIM activity. Cancer Lett., 2025. March 2. :217496. Impact factor: 9.7

Basu M, Xiao JF, Kailasam Mani SK, Qu F, Lin Y, Duex J, Ye H, Neang V, Theodorescu D. Genes driving three-dimensional growth of immortalized cells and cancer. Cell Death Dis. 2025;16(1):442. PMCID: PMC12152191. Impact factor: 9.6

Jimenez NR, Herman CR, Łaniewski P, Cope E, Lee K, Mahnert ND, Chase DM, Caporaso JG, Herbst-Kralovetz MM. Navigating complexities of polymorphic microbiomes in endometrial cancer. npj Biofilms and Microbiomes. NJP. 2025 May 22;11(1):1-8. https://doi.org/10.1038/s41522-025-00690-1. PMID: 40404643 Impact factor: 9.2

Smith KA, Batatinha H, Niemiro GM, Baker FL, Zúñiga TM, Diak D, Mylabathula PL, Kistner TM, Davini D, Hoffman E, Colombo JN, Seckeler M, Bond RA, Katsanis E, Simpson RJ. Exercise-induced β(2)-adrenergic receptor activation enhances effector lymphocyte mobilization in humans and suppresses lymphoma growth in mice through NK-cells. Brain Behav Immun. 2025 Apr 29;. doi: 10.1016/j.bbi.2025.04.040. [Epub ahead of print] PubMed PMID: 40311885. Impact factor: 8.8

Furlong MA, Liu T, Jung A, Beitel S, Hughes J, Krause R, Graber JM, Calkins MM, Calafat AM, Botelho JC, Huentelman M, Gulotta J, Goodrich JM, Burgess JL. Per- and polyfluoroalkyl Substances (PFAS) and microRNA: an epigenome-wide association study in firefighters. Environ Res. 2025; May 9:121766. Impact factor: 8.4

Jimenez NR,  Herman CR,  Laniewski P, Cope E, Lee K, Mahnert ND, Chase DM, Caporaso JG, Herbst-Kralovetz MM. Navigating complexities of polymorphic microbiomes in endometrial cancer. NPJ. Biofilms Microbiomes. 2025;11(1):85. PMCID: PMC12098703. Impact factor: 8

Bernardazzi C, Saha T, Gurney MA, Laubitz D, Dey PD, Masannat T, Sheikh IA, Midura-Kiela MT, Ghishan FK, Kiela PR. NHE3 Controls Proliferation and Migration of Colonic Epithelial Cells. Inflamm Bowel Dis. 2025, Feb. 17;. Impact factor: 7.3

Smith KA,  Batatinha H,  Niemiro GM,  Baker FL,  Zuniga TM,  Diak D,  Mylabathula PL,  Kistner TM,  Davini D,  Hoffman E,  Colombo JN,  Seckeler M,  Bond RA,  Katsanis E, Simpson RJ. Exercise-induced β(2)-adrenergic receptor activation enhances effector lymphocyte mobilization in humans and suppresses lymphoma growth in mice through NK-cells. Brain Behav Immun. 2025, Apr. 29;. Impact factor: 7.2

Morenz A, Ganguly A, Kessler L, Coronado G. Asking About Cervical Cancer Screening in National Surveys: Implications for Health Literacy and Research. Am J Prev Med.  2025, July 1. Impact factor: 6.6

Filioglou D, Santa-Cruz N, Leite GSF, Davini DW, Cracchiolo MJ, Baker FL, Husnain M, Simpson RJ, Voudouris V, Katsanis E. A Triple Oral Combination of Bendamustine, Acalabrutinib, and Venetoclax Demonstrates Efficacy Against Mantle Cell Lymphoma In Vitro and In Vivo. Cancers (Basel). 2025, May 14;17(11). PMCID: PMC12153862. Impact factor: 6.5

Mouneimne G,  Connors C,  Watson A,  Grant A,  Campo D,  Ring A,  Kaur P,  Lang JE. Mechanical Conditioning (MeCo) Score Progressively Increases Through the Metastatic Cascade in Breast Cancer via Circulating Tumor Cells. Cancers (Basel). 2025, May 12;17(10). PMCID: PMC12109637. Impact factor: 6.5

McDougal LM, Baker FL, Gustafson MP, Katsanis E, Simpson RJ. Exercise-mobilized donor lymphocyte infusions (DLI-X) enhanced with cytokine stimulation (DLI-XS) for the prevention and treatment of leukemic relapse after allogeneic hematopoietic cell transplantation. Front Immunol 2025 Jun 12;16:1563972. PMID: 40574863; PMCID: PMC12198174. Impact factor: 5.9

Baker FL, SJ, Cracchiolo MJ, Davini D, Simpson RJ., Katsanis E. Impact of post-transplant cyclophosphamide with bendamustine on immune reconstitution in young patients undergoing T-cell replete haploidentical bone marrow transplantation: results from a phase Ia/Ib clinical trial. Frontiers in Immunology. 2025, April 8; 16. Impact factor: 5.9

Filioglou D, Santa-Cruz N, Leite GSF, Davini DW, Cracchiolo MJ, Baker FL, Husnain M, Simpson RJ, Voudouris V, Katsanis E. A Triple Oral Combination of Bendamustine, Acalabrutinib, and Venetoclax Demonstrates Efficacy Against Mantle Cell Lymphoma In Vitro and In Vivo. Cancers. 2025, June 3. J5; 17(11):1889. Impact factor: 5.2

Barker K, Marco T, Husnain M, Katsanis E. Addition of Phosphorous and IL6 to m-EASIX Score Improves Detection of ICANS and CRS, as Well as CRS Progression. Cancers. 2025, June 3; 17(6):918.  Impact factor: 5.2

Conrad H,  Elkamel A,  Maltagliati A,  Wang K,  Hsu CH,  Linville W,  Lada M,  Sridhar P,  Worrell S. Outcomes of jejunostomy-tube placement in surgical patients with esophageal cancer. JTCVS Open. 2025, Jan. 20;24:496-509. PMCID: PMC12039437. Impact factor: 4.9

Daw J, Chung S, Chen CY, Heimark RL, Montfort WR. Real-Time Nitric Oxide Detection in Cytokine Stimulated Cancer Cells and Macrophages. Nitric Oxide. 2025, Feb. 28;. PMCID: PMC12009198. Impact factor: 4.4

Allen AM, Cao Q, Stayer LG, Luo X, Jensen J, Pang RD, Allen S, Donny EC, Benowitz N, Smith T,  Hatsukami D. Differences in Combustible Cigarette Smoking-Related Biomarkers by Hormonal Contraceptive Use: An Exploratory Study. Nicotine Tob Res. 2025, Jan. 30;. Impact factor: 4.2

Rocha AD, Long DJ, Drake WK, Galvez DB, Rice PF, Reed MN, Heusinkveld JM, Barton JK.  First Clinical Feasibility and Safety Study of a Novel Multimodality Fallopian Tube Imaging Endoscope. Lasers Surg Med. 2025, Feb. 1,; Impact factor: 4

Alsowaida YS, Alsolami A, Almangour TA, Abraham I. Infectious complications associated with immune and targeted anti-cancer therapies: a retrospective study of the FDA Adverse Events Reporting System (FAERS). Expert Opin Drug Saf. 2025, Feb. 1;. Impact factor: 4

Harel K, Czamanski-Cohen J, Cohen M, Caspi O, Weihs KL. Coping, Emotional Processing, and Cancer-Related Symptoms in Breast Cancer Survivors: Cross-Sectional Secondary Analysis of the REPAT Study. Psychooncology. 2025;34(2):e70094. 2025, Feb. 1; PMCID: PMC11785827. Impact factor: 3.9

Pontifex T, Yang X, Tracy A, Craig Z, Zhou C. Prenatal Exposure to Environmentally Relevant Low Dosage Dibutyl Phthalate Reduces Placental Efficiency in CD-1 Mice. Toxicol Sci.  2025, July 1; Impact factor: 3.8

Goodrich JM, Furlong MA, Urwin DJ, Gabriel J, Hughes J, Jung AM, Calkins MM, DuBose KN, Caban-Martinez AJ, Solle NS, Beitel SC, Burgess JL (CPCP). Epigenetic Modifications Associated With Wildland-Urban Interface (WUI) Firefighting. Environ Mol Mutagen. 2025, Jan. 1;. PMCID: PMC11905879. Impact factor: 3.6 

Fox RS, Brandon K, Badger TA, Gaumond JS, Morales AA, Ong JC, Parthasarathy S, Rini C, Zee PC,  Tanner EJ, Ancoli-Israel S, Penedo FJ, Siddique J,  Wu LM,  Reid KJ, Kaiser K. Stakeholder-informed  refinement of a behavioral sleep/circadian intervention for gynecologic cancer survivors: an application of the MOST preparation phase. Transl Behav Med. 2025;15(1). PMCID: PMC11795304. Impact factor: 3.6

Lima N,  DeLeon CM,  Sawyer TW. Polarimetry through a flexible imaging fiber bundle with a pixelated polarizer. Biomed Opt Express. 2025, April 1;16(4):1483-1498. PMCID: PMC12047709. Impact factor: 3.5

Galouzis N, Khawam M, Alexander EV, Mesropyan L, Luu C, Khreiss MR, Riall TS. Quality of Life and Social Health in Patients After Pancreatic Surgery. J Gastrointest Surg. 2025,  March 1;:101969. Impact factor: 3.5

Bea JW, Ochs-Balcom HM, Valencia CI, Chen Z, Blew RM, Lind KE, Caan BJ, Roe DJ, Rohan TE, Reeves KW,  Manson JE, Ballinger T, Reding KW,  Follis S, Ziller SG, Odegaard AO. Abdominal visceral and subcutaneous adipose tissue associations with postmenopausal breast cancer incidence. JNCI Cancer Spectr. 2025;. PMCID: PMC11879126. Impact factor: 3.4

Young S, Zarama D, DSouza D, Golzarian J, Anderson JK. Comparison of the safety and effectiveness of cryoablation for T1 renal cell carcinoma in organ or tissue transplant recipients as compared to non-transplant patients. Abdom Radiol (NY).  2025, June 12. Impact factor: 3.0

Marcarian HQ, Sivakoses A, Arias AM, Ihedioha OC, Lee BR, Bishop MC, et al. (2025) Renal cancer cells acquire immune surface protein through trogocytosis and horizontal gene transfer.  PLoS One. 2025, May 5;20(5). Impact factor: 3.2

Brar G, Shroff RT. Anti-PD-1 Therapy for Patients with Advanced Cholangiocarcinoma: Ready for Prime Time? J Immunother Precis Oncol. 2025, May 12;8(2):181-183. PMCID: PMC12080203. Impact factor: 3.2

Sivakoses A, Marcarian HQ, Arias AM, Lam AR, Ihedioha OC, Santamaria-Barria JA, Gurtner GC, Bothwell ALM. Triple negative breast cancer cells acquire lymphocyte proteins and genomic DNA during trogocytosis with T cells. PeerJ. 2025 Mar 31;13:e19236. doi: 10.7717/peerj.19236. PMID: 40183054; PMCID: PMC11967428. Impact factor: 3.06

Aromokeye R, Ackerman-Berrier M, Araujo RDC, Lambousis M, Cardoza S, Chen L, Kaplan ME, Zhu H,  Zerbinatti C, Penton C, Thatcher GRJ,  Marlowe T. Development of a high-throughput TR-FRET assay to identify inhibitors of the FAK-paxillin protein-protein interaction. SLAS Discov. 2025, May 1; 100237. Impact factor: 2.9

Harel K, Czamanski-Cohen J, Cohen M, Lane RD, Allen JJB, Caspi O, Weihs KL. Cardiac Vagal Control and Emotional Awareness Associated With Pain Among Breast Cancer Survivors. Psychophysiology. 2025, June 1;62(6):e70086. PMCID: PMC12134714. Impact factor: 2.9

Segrin C, Sikorskii A, Cunicelli N, Badger T. Moderators of interdependent psychological distress in cancer survivor-caregiver dyads. J Psychosoc Oncol. 2025, Jan. 9 :1-19. Impact factor: 2.6

Harris HR, Lind K, Fest S, Thomson CA, Saquib N, Shadyab AH, Schnatz PF, Robles-Morales R, Qi L, Strickler HD, Roe DJ, Farland LV. Infertility and risk of ovarian cancer in the women's health initiative. Cancer Causes Control. 2025, Jan. 29;. Impact factor: 2.5

Thompson J, Gautom P, Rivelli J, Johnson C, Burns M, Levell C, Hayes N, Coronado G. Faith-based Messaging and Materials for Colorectal Cancer Screening in the United States: Application of Boot Camp Translation within the African Methodist Episcopal Church. J Relig Health. 2024, Nov. 24; PMCID: PMC12103627. Impact factor: 2.0

Morenz AM, Nichols J, Snyder A, Perkins J, Prince DK, Ganzarski O, Hussein Z, Kim NJ, Dick A, Ng YH. Exploring Caregiver Support as a Potential Mediator of Neighborhood Socioeconomic Disadvantage and Reduced Likelihood of Liver Transplant Waitlisting. Transplant Direct. 2025 Mar 28;11(4):e1782. doi: 10.1097/TXD.0000000000001782. PMID: 40166626; PMCID: PMC11957614. Impact factor: 1.9

Segrin C, Sikorskii A, Cunicelli N, Badger T. Moderators of interdependent psychological distress in cancer survivor-caregiver dyads. J Psychosoc Oncol. 2025, Jan. 9;43(4):574-592.

Collaborators

List of cancer center members who were listed on a publication, but were not first, last or corresponding author.

Damiani T, Jarmusch AK ... Marty MT ... Wang M. A universal language for finding mass spectrometry data patterns. Nat Methods. 2025, May 12; Impact factor: 47.99

Knox JJ,  McNamara MG,  Bazin IS, Oh DY,  Zubkov O, Breder V, Bai LY, Christie A, Goyal L, Cosgrove DP, Springfeld C, Sjoquist KM,  Oh Park J, Verdaguer H, Braconi C, Ross PJ, De Gramont A, Shroff RT, Zalcberg JR, Palmer DH, Smith JR, Oelmann E,  Bruce T, Valle JW. A phase III randomised study of first-line NUC-1031/cisplatin vs. gemcitabine/cisplatin in advanced biliary tract cancer. J Hepatol. 2025, Feb. 18; Impact factor: 30

Buchanan C, Karunanithy G, Tkachenko O, Barber M, Marty MT, Nott TJ, Redfield C,  Baldwin AJ. Unidec NMR: automatic peak detection for NMR spectra in 1-4 dimensions. Nat Commun. 2025, Jan 7;16(1):449. PMCID: PMC11707349. Impact factor: 17.7

Palczewski MB, Kuschman HP, Hoffman BM, Kathiresan V, Yang H, Glynn SA, Wilson DL, Kool ET, Montfort WR, Chang J, Petenkaya A, Chronis C, Cundari TR, Sappa S, Islam K, McVicar DW, Fan Y, Chen Q, Meerzaman D, Sierk M, Thomas DD. Nitric oxide inhibits ten-eleven translocation DNA demethylases to regulate 5mC and 5hmC across the genome. Nat Commun. 2025, Feb. 18;16(1):1732. PMCID: PMC11836389. Impact factor: 17.7

Roland-McGowan JN, Freeman SC, Baghoomian W, Carroll BT, Kim CC, Curiel-Lewandrowski C, Chu EY,  Foster EL,  Nelson KC, White KP,  Ming ME,  Hartman RI, Leachman SA, Mengden-Koon S, Chen SC, Swetter SM, Prieto VG,  Berry E, Yu WY. Development of a Treatment Decision Aid for Patients with Dysplastic Nevi Who Are Candidates for Re-Excision. J Am Acad Dermatol. 2025, Jan. 7; Impact factor: 15.5

Nascimento de Lima P, Matrajt L, Coronado G,  Escaron AL, Rutter CM. Cost-Effectiveness of Noninvasive Colorectal Cancer Screening in Community Clinics. JAMA Netw Open. 2025;8(1):e2454938. 2025, Jan. 1;. PMCID: PMC11739995. Impact factor: 13.3

Ardalan B, Ciner A, Baca Y, Hinton A, Darabi S, Kasi A, Lou E, Azqueta JI, Xiu J, Datta J,  Shields AF, Aguirre A, Singh H, Shroff RT, Pishvaian MJ, Goel S. Distinct molecular and clinical features of specific variants of KRAS codon 12 in pancreatic adenocarcinoma. Clin Cancer Res. 2025, March 17;. Impact factor: 12.5

Naudin S,  Wang M,  Dimou N,  Ebrahimi E, Sawada N,  Schoemaker M,  Shu XO,  Sinha R,  Snetselaar L,  Stampfer MJ,  Stolzenberg-Solomon R,  Thomson CA, Ferrari P. Alcohol intake and pancreatic cancer risk: An analysis from 30 prospective studies across Asia, Australia, Europe, and North America. PLoS Med. 2025, May 20;22(5):e1004590. PMCID: PMC12091891. Impact factor: 11.6

Nguyen HTX, Kim BG, Myers JT,  Yan H,  Kumar S, Eid S,  Wang W, Huang AY, Liang FS. Engineering TME-gated inducible CAR-T cell therapy for solid tumors. Mol Ther. 2025, April 30; Impact factor: 11.4

Marroquin JM, Krall JR, Schliep K, Farland LV, Krishnamoorthi V, Kannan K, Pollack AZ. Per- and polyfluoroalkyl substances in eutopic endometrium tissue and risk of endometriosis: findings from the Investigating Mixtures of Pollutants and Endometriosis in Tissue (IMPLANT) Study. Environ Health Perspect. 2025, June 1;. PMCID: PMC12129303. Impact factor: 11.3

Zhang Y, Shi H, Wang Y, Liu W, Li G, Li D, Wu W, Wu Y, Zhang Z, Ji Y, Zhu C, Bai W, Lei H, Xu H, Zhong H, Han B, Yang L, Liu L, Wang W, Zhao Y, Zhang Y, Wu Y. Noscapine derivative 428 suppresses ferroptosis through targeting GPX4. Redox Biol. 2025, April 12;83:103635. Impact factor: 10.7

Juetten KJ, Sanders JD, Marty MT, Brodbelt JS. Combining Fourier Transform Ion Mobility with Charge Detection Mass Spectrometry for the Analysis of Multimeric Protein Complexes. Anal Chem. 2025, Jan. 14;97(1):140-146. Impact factor: 8

Gutmair K, Villa D, Cunningham N, Silkenstedt E,  Rimsza LM,  Ramsower CA, Scott DW, Gerrie AS, Kluin-Nelemans HC, Dreyling M, Hoster E. BR or R-CHOP induction with rituximab maintenance in untreated, transplant-ineligible patients with mantle cell lymphoma. Blood Adv. 2025, Feb. 21;. Impact factor: 7.6

Li D, Shen S,  Liu C,  Guo T,  Liu Y,  Pan P,  Zhao X,  Ma Y,  Li L,  Huang S,  Shen W,  YoupingZhang,  Jiang B,  Wang W,  Yin Q,  Zhang Y. Discovery of novel and highly potent anticancer agents enabled by selenium scanning of noscapine. Eur J Med Chem. 2025, April 30;293:117714. Impact factor: 7.0

Marcotte LM,  Khor S,  Reddy A,   Morenz A,  Nelson K,  Akinsoto N, Lee ES,  Onstad S, Wong ES. An analysis of multilevel factor contributions to breast cancer screening inequities in an academic health system. Cancer. 2025, Feb. 1;131(3):e35734. Impact factor: 6.9

Stimpson JP, Liao JM, Morenz AM, Joo JH, Wilson FA. A difference-in-differences analysis of Medicaid expansion and state paid sick leave laws on colorectal cancer screening. Cancer. 2025, May 15;131(10):e35904. PMCID: PMC12065529. Impact factor: 6.9

Abdelrahim M, Esmail A, Kim RD, Arora SP, Arshad J (CTOP), Kournoutas IA, ODonnell CD, Totev TI, Tan A, Mu F, Seshasayee SM, Hernandez S, Tran NH. Real-World Experiences Using Atezolizumab + Bevacizumab for the Treatment of Unresectable Hepatocellular Carcinoma: A Multicenter Study. Cancers (Basel). 2025, May 29;17(11). PMCID: PMC12153728. Impact factor:  6.5

Dommer J, Van Doorslaer K, Afrasiabi C, Browne K, Ezeji S, Kim L, Dolan M, McBride AA. PaVE 2.0: Behind the Scenes of the Papillomavirus Episteme. J Mol Biol. 2025, Aug. 1 ;:168925. Impact factor: 6.1

Chung V, Alistar A, Becerra C, Kasi A, Borazanci E,  Jameson GS, Roe DJ, Wertheim BC,  Cridebring D, Truitt M, Downes M,  Barrett MT, Korn R,  Lee K, Han H, Evans R, Von Hoff DD. Pembrolizumab ± paricalcitol in metastatic pancreatic cancer postmaximal cytoreduction. Oncologist. 2025, Jan 17;30(1). PMCID: PMC11756276. Impact factor: 5.8

Tan Y, Wang W, Xu L, Zhou X, Shen J, Zhou T, Duan C, Wang X, Liu Z, Wang M, Li G. Decellularized human amniotic member hydrogel promotes limbal stem cells proliferation. Colloids Surf B Biointerfaces. 2025 Aug;252:114656. doi: 10.1016/j.colsurfb.2025.114656. Epub 2025, Mar 29. PMID: 40168696. Impact factor: 5.4

Chen J,  Trindl CA,  Ye H,  Huang D,  Ooi A,  Garcia JGN,  Chapman E,  Zhang DD. CYP4F11, an NRF2 Target Gene, Promotes Hepatocellular Carcinoma Cell Growth. Mol Carcinog. 2025, May 6; Impact factor: 5.1

Fest SN, Farland LV, Doody DR, Eliassen AH, Rosner BA, Fung TT, Hankinson SE, Kensler TW, Willett WC, Harris HR. Hormone-associated dietary patterns and premenopausal breast cancer risk. Breast Cancer Res Treat. 2025, July 1. Impact factor: 4.6

Gemmill JAL, Thompson P, Batiste R, Vacchi-Suzzi C, Preece C, Cohen J, Baer L, Mies C, Turner M, Russell CA, Stopeck A. Metastatic breast cancer through the Oncotype DX Breast Recurrence Score®: insights from a small cohort study. Breast Cancer Res Treat. 2025, May 28; Impact factor: 4.6

Deressa BT, Pierz A, Jyung H, Rosario B, Andoh-B-Baidoo N, Tibebu B,  Seife E, Bekele E, Hussein R,  Gedif T, Madhivanan P, Lott B. A qualitative study on the psycho-oncological experiences of women navigating breast cancer diagnosis, treatment, and survivorship in Ethiopia. J Cancer Surviv. 2025, Feb. 8; Impact factor: 4.4

Zhao YJ, Zhang SY, Wei YY,  Li HH,  Lei W, Wang K, Kumar S, Zhou C, Zheng J. An Endogenous Aryl Hydrocarbon Receptor Ligand Dysregulates Endothelial Functions, Transcriptome, and Phosphoproteome. Am J Physiol Cell Physiol. 2025, March 1; Impact factor: 4.2

Weinfeld-Yehoudayan A, Czamanski-Cohen J, Weihs KL, Cohen M. Using Drawings to Measure Emotional Processing in Breast Cancer Survivors and Its Association With Depression, Pain, and Fatigue. Psychooncology. 2025, Feb. 1;34(2):e70099. PMCID: PMC11813831. Impact factor: 3.9

Domanico MC, Collette NM, Ubick E, Ding X,  Buchholz BA, Van Winkle LS. DNA adducts form in mouse lung and liver after oral naphthalene exposure. Toxicol Sci. 2025, Feb. 8; Impact factor: 3.8

Perez K,  Del Rivero J,  Kennedy EB,  Basu S,  Chauhan A,  Connolly HM,  Dasari AN,  Gangi A,  Clarke CN,  Hallet J,  Howe JR,  Grady E,  Ivanidze J,  Mittra ES,  White SB,  Raj NP,  Vijayvergia N,  Lewis MA,  Chan JA,  Kunz PL,  Mailman J,  Arshad J, Bergsland EK. Symptom Management for Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline. JCO Oncol Pract. 2025, May 9;:OP2500133. Impact factor: 3.4

Hagio T, Galons JP,  Roe D, Marron MT, Thomson C, Thompson P, Stopeck AT, Bilgin A, Altbach MI, Chiang JA. Concurrent water T(2) and fat fraction mapping of the breast using the radial gradient and spin echo (RADGRASE) pulse sequence. Magn Reson Imaging. 2025,  Feb. 1:110355. Impact factor: 3.1

Warner EL, Sikorskii A, Cunicelli N, Badger T, Segrin C, Morrill KE, Rainbow J. Employment productivity and cancer-related psychological symptoms among adult cancer dyads. J Occup Environ Med. 2025, Jan. 30;. Impact factor: 2.3

Ko AH, Chao J, Noel MS, Shankaran V, Sohal D, Crow M, Oberstein PE, Scott AJ, McRee AJ, Rocha Lima CMSP,  Fong L, Keenan BP, Soto M, Filbert EL, Hsu FJ, Yang X. A Phase 2 Study of Sotigalimab, a CD40 Agonist Antibody, Plus Concurrent Chemoradiation as Neoadjuvant Therapy for Esophageal and Gastroesophageal Junction Cancers. Cancer Res Commun. 2025, Feb. 1;. PMCID: PMC11843624. Impact factor: 2

Carson WO, Little A, Monetathchi A, Erdrich J, Cordova-Marks FM. Analysis of Urban Indian Organizations' Promotion of Cancer Services. Cancer Res Commun. 2025, Feb. 1;. PMCID: PMC11863186. Impact factor: 2

Su Y, Orchard TS, Shadyab AH, Skiba MB, Snetselaar L, Vitolins MZ, Richey PA, Coday M, Zaslavsky O. Mediterranean Diet and Change in Physical Function Over Time In Older Women. J Nutr Gerontol Geriatr. 2025, Apr-Jun; 44(2):73-89. doi: 10.1080/21551197.2025.2484528. Epub 2025 Apr 3. PMID: 40179014. Impact factor: 1.39

Tseng HW, Vedantham S, Fu Z. Simultaneous Reduction of Radiation Dose and Scatter-to-Primary Ratio using a Truncated Detector and Advanced Algorithms for Dedicated Cone-Beam Breast CT. Biomed Phys Eng Express. 2025, March 3;. Impact factor: 1.3